digene HC2 High-Risk HPV DNA Test

For detection of human papillomavirus infections using Hybrid Capture 2 technology

  • Detection of 13 high-risk HPV types
  • High clinical sensitivity proven by extensive clinical validation
  • Standardized, objective results
  • HPV test for in vitro diagnostic use
  • Uses full genome probes
The digene HC2 High-Risk HPV DNA Test is an in vitro nucleic acid hybridization assay with signal amplification and chemiluminescence for the qualitative detection of 13 types of human papillomavirus (HPV) in cervical specimens. The test is suitable for high- or low-volume testing.
Product Product no. Cat. no. List price:
Show details
Can't order online?
To place an order via phone, email or for requesting a quote, please provide the product’s name, number and catalog number.
Product Cat. no. List price:
digene HC2 High-Risk HPV DNA Test
For 88 cervical samples (96 tests): Probe Diluent, High-Risk HPV Probe, Quality Controls, Calibrator, Capture Microplate, Reagents and Buffers (additional Wash Buffer Concentrate is available [Cat. no. 5100-00047], but is normally not needed); for use in Canada
Add to cart

The digene HC2 High-Risk HPV DNA Test is intended for in vitro diagnostic use.

  • Main Image Navi
HC2 vs. PCR.|In vitro diagnostic device.|
Clinical vs. analytical sensitivity. The clinically validated cutoff value of the HC2 test (5000 copies) has been established after extensive clinical research.||
The digene HC2 High-Risk HPV DNA Test is FDA-approved for in vitro diagnostic use (see IVD mark). Using Hybrid Capture 2 technology for HPV testing offers the following benefits when compared with PCR for HPV testing:
Standardized method
Clinically relevant sensitivity (figure HC2 vs. PCR)
Reliability — 10 million tests/year worldwide
Less risk of false negatives due to inhibition 

The digene HC2 High-Risk HPV DNA Test detects the presence of 13 high-risk HPV types (16/18/31/33/35/39/45/51/52/56/58/59/68, which are carcinogenic) using full genome probes complementary to HPV DNA, specific antibodies, signal amplification, and chemiluminescent detection. It analyzes HPV DNA high-risk groups in cervical specimens.

The digene HC2 High-Risk HPV DNA Test has been approved for use with the digene HC2 DNA Collection Device, digene HC2 Sample Conversion Kit, digene Cervical Sampler, digene Specimen Transport Medium, and PreservCyt Solution (Hologic), depending on country regulations. Automated options for the digene HC2 High-Risk HPV DNA Test include the Rapid Capture System (for high-volume sample throughput testing); guidelines vary among countries. 


The digene HC2 High-Risk HPV DNA Test uses advanced, Hybrid Capture 2 technology to directly detect HPV. It is the most widely accepted HPV test, providing extensive validation in conjunction with Pap in clinical studies.

The digene HC2 High-Risk HPV DNA Test detects the presence of 13 high-risk types using full genome RNA probes complementary to the HPV DNA, specific antibodies, and chemiluminescent detection. The target DNA combines with specific RNA probes, creating RNA:DNA hybrids. Then, the RNA:DNA hybrids are captured onto a solid phase coated with universal capture antibodies specific for RNA:DNA hybrids. The specimen matrix is then washed from the captured hybrids to remove inhibitors. During the signal amplification, captured RNA:DNA hybrids are detected with multiple antibodies conjugated to alkaline phosphatase. The signal resulting from the chemiluminescent reaction is read and the results are automatically interpreted.


The digene HC2 High-Risk HPV DNA Test is used to screen patients with ASC-US (atypical squamous cells of undetermined significance) Pap results to determine the need for referral to colposcopy. The results of this test are not intended to prevent women from proceeding to colposcopy.

In women 30 years of age and older, the digene HC2 High-Risk HPV DNA Test can be used with Pap to adjunctively screen to assess the presence or absence of high-risk HPV types. Guidelines for use of the HPV Test vary between countries, but in countries such as the USA, experts recommend that women 30 years of age and older get the HPV Test along with the Pap test. The presence or absence of high-risk HPV types, together with the physician's risk assessment of cytology history, other risk factors, and professional guidelines, may be used to guide patient management.

You are not authorized to download the resource

QIAGEN Websites
HPV information for women and physicians